Professional Summary
Professional Overview
Paolo Fiorina is a renowned endocrinologist and co-founder with extensive expertise in the field of Type 1 Diabetes (T1D). As the Co-Founder of Altheia Science and Enthera Pharmaceuticals, he is actively shaping the future of endocrinology and pharmaceutical development to address unmet needs in T1D management.
Experience Summary
Current Roles
Co-Founder, Altheia Science (2019 - Present)
- Co-founded the biotechnology company Altheia Science, which focuses on developing innovative therapies for autoimmune and inflammatory diseases, with a particular emphasis on T1D.
- Provides strategic direction and oversees the company's research and development efforts, leveraging his deep expertise in endocrinology and T1D.
Chief of Endocrinology, Fatebenefratelli-Sacco-Macedonio Melloni-Buzzi Hospitals (2017 - Present)
- Serves as the Chief of Endocrinology at the renowned Fatebenefratelli-Sacco-Macedonio Melloni-Buzzi Hospitals, leading a team of endocrinologists and overseeing the delivery of comprehensive endocrine care.
- Drives the implementation of cutting-edge endocrine treatments and the advancement of patient outcomes through research and innovation.
Co-Founder, Enthera Pharmaceuticals (2018 - Present)
- Co-founded Enthera Pharmaceuticals, a biotechnology company focused on the development of novel therapies for autoimmune and inflammatory diseases, with a particular emphasis on T1D.
- Provides strategic guidance and scientific expertise to the company's research and development initiatives, with the goal of bringing transformative treatments to the market.
Career Progression
Prior to his current roles, Paolo Fiorina held the position of Professor of Endocrinology at the Università degli Studi di Milano since 2017. He also served as the Director of the International Center for T1D at the Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Ospedale Sacco, since 2017.
Throughout his distinguished career, Dr. Fiorina has made significant contributions to the field of endocrinology, particularly in the areas of T1D research and clinical management. His research has been published in numerous peer-reviewed journals, and he has been recognized for his innovative approaches and dedication to improving the lives of patients with endocrine disorders.
Academic Background
Paolo Fiorina holds a medical degree from the Università degli Studi di Milano, where he also completed his specialization in Endocrinology. He has continued to deepen his expertise through ongoing research and clinical practice, making him a respected authority in the field of endocrinology.
Areas of Expertise
- Type 1 Diabetes (T1D) management and research
- Endocrinology, with a focus on autoimmune and inflammatory diseases
- Translational research and drug development for endocrine disorders
- Clinical leadership and patient-centric care
- Collaborative research and international scientific collaborations
Professional Impact
Dr. Fiorina's contributions to the field of endocrinology have been significant, as evidenced by his leadership roles in academic and clinical settings, as well as his co-founding of two biotechnology companies focused on developing innovative therapies for T1D and other endocrine disorders. His work has had a direct impact on advancing the understanding and treatment of these conditions, ultimately improving the lives of patients worldwide.
Conclusion
Paolo Fiorina's extensive expertise, entrepreneurial spirit, and unwavering commitment to advancing the field of endocrinology make him a valuable asset in the healthcare and biotechnology industries. As a co-founder of Altheia Science and Enthera Pharmaceuticals, he continues to drive progress in the development of novel therapies for autoimmune and inflammatory diseases, with a particular focus on transforming the management of Type 1 Diabetes.
